Comparative effectiveness of azithromycin versus roflumilast in patients with chronic obstructive pulmonary disease: emulated target trial.

Azithromycin reduces the risk of moderate or severe COPD exacerbations by 17% compared to roflumilast in routine clinical practice among patients over 40.

• Why it matters: COPD exacerbations significantly impact patient health and healthcare resources, yet direct comparisons of treatment options like azithromycin and roflumilast are limited in real-world settings.
• What they did: Using emulated target trial methodology, researchers analyzed data from 7,550 matched patients initiating either medication, focusing on time to first exacerbation and hazard ratios.
• The result: Azithromycin was associated with a lower hazard of exacerbation (hazard ratio 0.83), suggesting it may be more effective in preventing COPD worsening, informing treatment decisions.